Patents Assigned to Genus Oncology, LLC
  • ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
    Publication number: 20220049014
    Abstract: The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Application
    Filed: October 5, 2021
    Publication date: February 17, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
    Patent number: 11136410
    Abstract: The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: October 5, 2021
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
    Patent number: 10617773
    Abstract: The present disclosure is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 14, 2020
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
    Patent number: 10059775
    Abstract: The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: August 28, 2018
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
    Publication number: 20180036441
    Abstract: The present disclosure is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 8, 2018
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
    Patent number: 9789156
    Abstract: The treatment of human epidermal growth factor receptor 2-positive (HER2+) cancers using a combination of anti-mucin 1 (anti-MUC1) therapy and anti-human epidermal growth factor receptor 2 (anti-HER2) therapy is described, such as the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 17, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics
    Patent number: 9572855
    Abstract: The invention provides for treatment of MUC1+/ER?+/? cancers using an anti-MUC1 therapy, optionally including an anti-ER? therapy. In particular, the invention addresses the treatment of tamoxifen-resistant cancers, using MUC1+, and optionally anti-ER? therapy.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 21, 2017
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • MUC-1 cytoplasmic domain peptides as inhibitors of cancer
    Patent number: 9546201
    Abstract: Peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 17, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
    Publication number: 20160340442
    Abstract: The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Application
    Filed: January 29, 2015
    Publication date: November 24, 2016
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • COMBINATION ANTI-HER2 CANCER THERAPY USING MUC1 PEPTIDES AND CHEMOTHERAPEUTICS
    Publication number: 20160074468
    Abstract: The invention provides for treatment of HER2+ cancers using a combination of anti-MUC1 therapy and anti-HER2 therapy. In particular, the invention addresses the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents.
    Type: Application
    Filed: March 10, 2014
    Publication date: March 17, 2016
    Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • COMBINATION ANTI-ESTROGEN RECEPTOR CANCER THERAPY USING MUC1 PEPTIDES AND CHEMOTHERAPEUTICS
    Publication number: 20160058827
    Abstract: The invention provides for treatment of MUC1+/ER?+/? cancers using an anti-MUC1 therapy, optionally including an anti-ER? therapy. In particular, the invention addresses the treatment of tamoxifen-resistant cancers, using MUC1+, and optionally anti-ER? therapy.
    Type: Application
    Filed: March 10, 2014
    Publication date: March 3, 2016
    Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • Inhibition of inflammation using antagonists of MUC1
    Patent number: 9096687
    Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 4, 2015
    Assignees: Genus Oncology, LLC, Dana-Farber Cancer Institute, Inc.
    Inventors: Donald W. Kufe, Surender Kharbanda
  • MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER
    Publication number: 20150152152
    Abstract: Peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.
    Type: Application
    Filed: February 12, 2015
    Publication date: June 4, 2015
    Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • Treating MUC1-expressing cancers with combination therapies
    Patent number: 9044421
    Abstract: The invention provides method of treating cancers that express mucin 1 (MUC1) by the administration of phosphatidylinositol 3-kinase (PI3-K) inhibitors in combination with MUC1-directed cancer therapies. The PI3-K inhibition may advantageously be combined with peptides that inhibit MUC1 oligomerization, or further with other standard anticancer therapies such as chemo-, radio- and surgical therapies.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: June 2, 2015
    Assignees: Genus Oncology, LLC, Dana-Farber Cancer Institute, Inc.
    Inventors: Donald Kufe, Surender Kharbanda
  • MUC-1 cytoplasmic domain peptides as inhibitors of cancer
    Patent number: 8957185
    Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: February 17, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Small molecule inhibitors of MUC1 and methods of identifying the same
    Patent number: 8952054
    Abstract: The invention provides methods for the identification of small molecules that inhibit MUC1 oligomerization, and the functions flowing therefrom. In addition, small molecules that prevent MUC1 oligomerization are disclosed. Identified molecules will find use in treating a variety of MUC1-related inflammatory conditions, including MUC1-related cancers.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: February 10, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • ANTAGONISTS OF MUC1
    Publication number: 20140322332
    Abstract: The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 30, 2014
    Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • INHIBITION OF INFLAMMATION USING ANTAGONISTS OF MUC1
    Publication number: 20140187494
    Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • Antagonists of MUC1
    Patent number: 8685928
    Abstract: The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: April 1, 2014
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC.
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Inhibition of inflammation using antagonists of MUC1
    Patent number: 8614186
    Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: December 24, 2013
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC.
    Inventors: Donald W. Kufe, Surender Kharbanda